APPROVED FOR THE TREATMENT OF IPF, SSc-ILD AND PF-ILD
FACE PULMONARY FIBROSIS
and modify disease progression by slowing lung function decline1-6
OFEV® (nintedanib) is approved for the treatment of progressive fibrosing interstitial lung disease (PF-ILD).
systemic sclerosis-associated interstitial lung disease (SSc-ILD) and idiopathic pulmonary fibrosis (IPF).1
systemic sclerosis-associated interstitial lung disease (SSc-ILD) and idiopathic pulmonary fibrosis (IPF).1
Learn how acute exacerbation of IPF can impact the course of the disease
Document ID: PC-MY-101488
07/01/2022
Author: Boehringer Ingelheim
Low FVC is the most consistent risk factor for acute exacerbation in IPF patients. [1] Patients with an AE-IPF have a worse prognosis and higher mortality rate. [2]
References:
1. Collard HR, et al. Am J Respir Crit Care Med. 2016;194:265-75.
2. Song JW, et al. Eur Resp J. 2011;37:356-363.
RELATED CONTENT
PC-MY-101488
Production date: January 2022
Production date: January 2022